teremia without a clinical focus in 14.6%. The overa ll case fata li ty rate for invasive pneumococcal disease was 11 %. Sixty per cent of those with invasive pneumococcal disease were eligible for immunization, according to the nationally established criteria. Of the 31 different capsu lar types identified, the five most frequent were 14, 4, 6B, 9V, 18C and 19F. Ninety-four per cent of iso lates were types included in the current 23-valent pneumococcal vaccine. Among ch ildren two years of age and younger, 89% of isolates would be included in a proposed 7-valent pneumococca l conjugate vaccine currently undergoing clinical eva lu ation. Diminished susceptibility to penici llin (high level and intermediate) was observed in 7.4% of invasive pneumococca l isolates, and diminished susceptibility was also seen to ceftriaxone (3.8%), erythromycin (3.8%), ofloxacin (4.0%) and trimethoprim/sul fa methoxazole (16.1 %). Two per cent of isolates were resistant to three or more classes of antibiotic.
The SHUSS has provided important population-based epidemiological and microbiological data about invas ive pneumococcal infection that may be used to support and eva luate publicly funded immunization programs in Canada.
